FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine, in particular oncology, and discloses a method for estimating the risk of recurrence of ovarian cancer in patients after completion of combination therapy. Method includes a cytoreductive surgery and a chemotherapy based on platinum drugs, calculating the probability value by the formula, determined with the help of logistic regression, taking into account the level of the HE-4 oncomarker after the end of first-line chemotherapy, tumor histotypes, category and subcategory of the tumor stage.
EFFECT: method is high sensitive and specific, allows to carry out the forecast of repeated cancer growth up to the clinical appearance of relapse, to optimize the diagnostic algorithm and to take treatment-and-prophylactic steps well-timed.
1 cl, 3 tbl, 1 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF RISK OF TUMOUR PROGRESSION IN PATIENTS WITH OVARIAN CANCER | 2023 |
|
RU2816339C1 |
| METHOD FOR PREDICTION OF PROBABILITY OF POSSIBLE EXECUTION OF OPTIMUM CYTOREDUCTIVE OPERATION IN PATIENTS WITH DISSEMINATED FORMS OF OVARIAN CANCER | 2017 |
|
RU2637399C1 |
| METHOD FOR EARLY DIAGNOSIS OF PERITONEAL OVARIAN CANCER RECURRENCE AFTER OPTIMUM CYTOREDUCTIVE SURGERY | 2014 |
|
RU2583114C1 |
| METHOD FOR PREDICTING RECURRENCE OF SEROUS OVARIAN CARCINOMA | 2020 |
|
RU2749361C1 |
| METHOD OF TREATING OVARIAN CANCER, VERSIONS OF ITS METASTASIS AND RECURRENCE | 2015 |
|
RU2582939C1 |
| METHOD FOR PREDICTING THE RELAPSE OF SEROUS OVARIAN CANCER | 2005 |
|
RU2290078C1 |
| METHOD FOR DIAGNOSTICS OF HIGH-GRADE OVARIAN CARCINOMA SENSITIVE TO BRCA-SPECIFIC DRUGS | 2021 |
|
RU2774160C1 |
| METHOD FOR DETERMINING THE EFFECTIVENESS OF CHEMOTHERAPY WITH PLATINUM PREPARATIONS IN III-IV STAGE OVARIAN CANCER | 2020 |
|
RU2738167C1 |
| METHOD OF PREDICTING RISK OF EARLY RECURRENCE OF ENDOMETRIAL SQUAMOUS CELL CARCINOMA IN PATIENTS WITH STAGE I OF DISEASE | 2023 |
|
RU2812609C1 |
| METHOD OF DETERMINATION OF ORIENTATION OF PATHOLOGICAL PROCESS AT CANCER OF OVARIES | 2007 |
|
RU2350966C1 |
